Cara Therapeutics Inc

NASDAQ:CARA 4:00:00 PM EDT

1.71

+0.04 (+2.40%)

: $1.72 +0.01 (+0.57%)

Market Cap (Intraday)	92.48M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$10.69 Million
Adjusted EPS	-$0.51

See more estimates

10-Day MA	$1.84
50-Day MA	$2.62
200-Day MA	$5.75

See more pivots

Cara Therapeutics Inc Stock, NASDAQ:CARA

4 Stamford Plaza, 107 Elm Street, Stamford, Connecticut 06902

United States of America

Phone: +1.203.406.3700

Number of Employees: 106

http://www.caratherapeutics.com

Description

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.